David Hsiehchen

17PUBLICATIONS
117CO-AUTHORS
Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 21, 2026
Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial.

|Jun 13, 2026
Deciphering small sequence differences in T cell receptor-antigen pairing.

|Jan 16, 2026
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab.

Saiabhiroop Govindu, Prashanth Gowda, Maishara Muquith

|Oct 20, 2025
Impact of Tumor Burden on Immune Checkpoint and Conventional Therapy Responses and Outcomes.

Prashanth Gowda, Saiabhiroop R Govindu, David Hsiehchen

|Jul 30, 2025
Racial and Ethnic Disparities in Survival among Patients with Cholangiocarcinoma in the United States: A Systematic Review and Meta-analysis.

Andrew D Shubin, Phillip J Leff, Meena M Tadros

|Jul 01, 2025
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial.

David Hsiehchen, Radhika Kainthla, Heather Kline

Pageof 3

Frequent Collaborators

4 joint publications

Hao Zhu

3 joint publications

Amit G Singal

2 joint publications

Nina N Sanford

2 joint publications

Adam C Yopp